Related Experiment Video
Updated: Sep 29, 2025

Minimal Erythema Dose MED Testing
Published on: May 28, 2013
Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases
Massimo Petruzzi1,2, Sara Galleggiante1, Sabrina Messina1
1Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
Insights
Four patients experienced oral erythema multiforme flares after receiving the BNT162b2 COVID-19 vaccine. This rare side effect, potentially linked to the vaccine or reactivated herpes virus, was treated with corticosteroids.
Area of Science:
- Dermatology
- Immunology
- Vaccinology
Background:
- The COVID-19 pandemic necessitates widespread vaccination, with BNT162b2 being a key vaccine.
- Adverse events following vaccination are documented, including various cutaneous reactions.
- Erythema multiforme is a recognized mucocutaneous reaction pattern.
Observation:
- Four cases of oral erythema multiforme flares post-BNT162b2 vaccination are presented.
- Patients had no prior history of similar lesions or herpes infections.
- Lesions appeared after the first or second vaccine dose, with some cases showing both oral and cutaneous involvement.
Findings:
- The BNT162b2 vaccine may trigger erythema multiforme flares.
- The exact causal link is unproven, but medication-induced erythema multiforme is known.
- Reactivation of latent herpes virus infection by the vaccine is a potential mechanism.
Implications:
- Highlights a rare potential adverse effect of the BNT162b2 COVID-19 vaccine.
- Suggests vigilance for mucocutaneous reactions post-vaccination.
- Warrants further investigation into vaccine-associated erythema multiforme and herpes virus reactivation.
Background:
The 2019 Coronavirus disease (Covid-19) has affected thousands of people worldwide. To date, vaccines appear to be the only method to prevent and reduce mortality. Four vaccinations have been outwardly approved by European Medicine Agency (EMA) in Europe: BNT162b2 (Comirnaty-BioNTech/Pfizer), mRNA-1273 (Spikevax-Moderna), ChAdOx1 (VaxzevriaAstrazeneca), and Ad26.COV2-S (Janssen-Johnson&Johnson). After vaccination, local and systemic adverse effects can occur. Cutaneous reactions like urticaria, local injection site pain, morbilliform rash have been documented after vaccination.
Cases Presentation:
We report four cases of oral erythema multiforme flare arising after BNT162b2 vaccination administration. All the patients denied previous erythema-like and herpetic manifestations history. Two of the reported cases (number 1 and 2) presented with both oral and cutaneous lesions, while cases 3 and 4 showed only oral manifestations. Three of the cases presented the erythema after the first vaccination dosage administration, only one case reported lesions after the second vaccination dosage administration. All the cases were treated with prednisone via oral administration and topical 0.05% clobetasol ointment.
Conclusions:
The present reports represent some of the few cases of erythema multiforme occurring as a side effect of the BNT162b2 COVID-19 vaccination. The causal role of the vaccine for the erythema multiforme has not been proven yet; nevertheless, it is not uncommon for medications to trigger this disease. The vaccine could surface a silent herpes virus infection, which would induce the erythema multiforme instead.
More Related Videos
06:31Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
Published on: October 3, 2019
09:37Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Related Concept Videos
Cross-reactivity
Endocarditis II: Clinical Features of Infective Endocarditis
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Allergic Reactions
Allergic Drug Reactions